Ablynx is looking for new partners to take its rheumatoid arthritis drug vobarilizumab into phase 3 development, after AbbVie turned down an option to license the drug. AbbVie has already paid the ...

Sanofi has leapt in to buy Ablynx for €3.9 billion ($4.85bn) outbidding an offer from Novo Nordisk which the European biotech had declined two weeks ago. For Sanofi, the acquisition comes hot on ...

Finally, Ablynx has entered ALX-0081 into development for the treatment of coronary syndromes, the first dromedary-derived V HH molecule in clinical development. MAbs have historically been ...

Round co-led by BGF, Octopus Ventures and M Ventures, with support from new corporate investor, Eli Lilly and Company, and ...

Thus, Ghent, Belgium–based Ablynx is developing a class of antibody fragment based on a single variable domain, a hinge region and two constant domains (CH2 and CH3) derived from llama antibodies.

MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11ZUG, Switzerland, September 9, 2024 – MoonLake ...

NanoSyrinx, the synthetic biology company developing ‘nanosyringes’ as a novel platform for targeted intracellular delivery ...

MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11 ZUG, Switzerland, September 9, 2024 - MoonLake Immunotherapeutics AG ("MoonLake"; Nasdaq: MLTX), a clinical-stage ...